AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk powder
Number of subjects: 64
Study 8901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium tablets
Number of subjects: 64
Study 8901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for milk powder group
Number of subjects: 64
Study 8901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for calcium tablet group
Number of subjects: 64
Study 8901793 — intervention group
Group type: COMPARATOR
Intervention: Advice on dietary calcium supplementation and fat reduction
Number of subjects: 64
Study 1667473 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice containing 3.3% soluble pyrophosphate and 1.0% Gantrez copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0
Study 1667473 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 0
Study 1667473 — intervention group
Group type: COMPARATOR
Intervention: Customary oral hygiene procedures
Number of subjects: 0
Study 6351894 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir ointment, applied five times a day for 5 days
Number of subjects: 13
Study 6351894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13
Study 31399139 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid felt reinforcement
Number of subjects: 514
Study 31399139 — intervention group
Group type: COMPARATOR
Intervention: Control (previous anastomosis methods)
Number of subjects: 514
Study 27992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulation of time spent in moderate-to-vigorous-intensity PA and sedentary time (Study 1)
Number of subjects: 0
Study 27992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of sedentary behavior while holding exercise constant (Study 2)
Number of subjects: 0
Study 27992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exercise, decreased sedentary time, or both (Study 3)
Number of subjects: 0
Study 27992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of 3-month reliability for the pattern metrics (Study 4)
Number of subjects: 0
Study 26856258 — intervention group
Group type: EXPERIMENTAL
Intervention: Telekit intervention
Number of subjects: 116
Study 26856258 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 24846619 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX + harm‐reduction counseling
Number of subjects: 300
Study 24846619 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + harm‐reduction counseling
Number of subjects: 300
Study 24846619 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm‐reduction counseling only
Number of subjects: 300
Study 24846619 — intervention group
Group type: COMPARATOR
Intervention: Community-based, supportive-services-as-usual
Number of subjects: 300
Study 22845494 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol 50 mg
Number of subjects: 0
Study 22845494 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol 75 mg
Number of subjects: 0
Study 22845494 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 0
Study 22845494 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol (unspecified dosage)
Number of subjects: 0
Study 19219261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3x (G3) - 1 hour of physical exercise, 3 times/week for 20 weeks
Number of subjects: 40
Study 19219261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5x (G5) - 1 hour of physical exercise, 5 times/week for 20 weeks
Number of subjects: 40
Study 19219261 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - encouraged to engage in a physical exercise program
Number of subjects: 40
Study 17533178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (50 microg per nostril per day) for 40 days
Number of subjects: 60
Study 17533178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17533178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intranasal steroid treatment on alternate days for the first 2 weeks per month (group A1)
Number of subjects: 60
Study 17533178 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued daily mometasone treatment for the first 2 weeks per month (group A2)
Number of subjects: 60
Study 17533178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone treatment
Number of subjects: 60
Study 15621710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetal formulation of superoxide dismutase (SOD)
Number of subjects: 20
Study 15621710 — intervention group
Group type: COMPARATOR
Intervention: SOD group
Number of subjects: 20
Study 11203778 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP (restoration + zinc phosphate cement)
Number of subjects: 12
Study 11203778 — intervention group
Group type: EXPERIMENTAL
Intervention: GI (restoration + resin‐modified glass‐ionomer cement)
Number of subjects: 12
Study 11203778 — intervention group
Group type: COMPARATOR
Intervention: C2 (no restoration and pH cycling)
Number of subjects: 12
Study 11203778 — intervention group
Group type: COMPARATOR
Intervention: C1 (no restoration and no pH cycling)
Number of subjects: 12
Study 9664089 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 20
Study 9664089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7530473 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (2 mumol min-1) with bradykinin (100 pmol min-1)
Number of subjects: 8
Study 7530473 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mumol min-1) with bradykinin (100 pmol min-1)
Number of subjects: 8
Study 7530473 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (2 mumol min-1) with substance P (1 pmol min-1)
Number of subjects: 8
Study 7530473 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mumol min-1) with substance P (1 pmol min-1)
Number of subjects: 8
Study 3292363 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine at a dose of 2 mg per kg
Number of subjects: 47
Study 3292363 — intervention group
Group type: COMPARATOR
Intervention: Conventional combination regimen of azathioprine (1 mg per kg) with prednisolone
Number of subjects: 47
Study 3292363 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid withdrawal
Number of subjects: 47
Study 3292363 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine group
Number of subjects: 47
Study 31682162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acumapimod 75 mg repeated single-dose on Days 1 and 6
Number of subjects: 183
Study 31682162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 31682162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 40 mg (10 days)
Number of subjects: 183
Study 31682162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acumapimod 20 mg single-dose
Number of subjects: 183
Study 28903510 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL (400 mg twice daily)
Number of subjects: 39
Study 28903510 — intervention group
Group type: COMPARATOR
Intervention: EFV plus 2 nucleoside analogues
Number of subjects: 39
Study 25237119 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 43
Study 23927483 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-calorie well-balanced meal (WB500)
Number of subjects: 32
Study 23927483 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-calorie well-balanced meal (WB250)
Number of subjects: 32
Study 23927483 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-calorie high-fat meal (HF250)
Number of subjects: 32
Study 23927483 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-calorie well-balanced liquid meal (Ensure®)
Number of subjects: 32
Study 21240871 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB group (valsartan 40-80 mg daily for 6 months)
Number of subjects: 35
Study 21240871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 21240871 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB group
Number of subjects: 35
Study 19406981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg plus isoniazid placebo
Number of subjects: 328
Study 19406981 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid 300 mg plus moxifloxacin placebo
Number of subjects: 328
Study 19406981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin group
Number of subjects: 328
Study 19406981 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid group
Number of subjects: 328
Study 16505413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI)
Number of subjects: 135
Study 12934979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 211
Study 12934979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 12934979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 211
Study 10829320 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative visualization therapy (Group A)
Number of subjects: 208
Study 10829320 — intervention group
Group type: COMPARATOR
Intervention: No preoperative therapy (Group B)
Number of subjects: 208
Study 8891847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha (5 MU/m2 thrice a week for 26 weeks)
Number of subjects: 38
Study 8891847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha combined with deflazacort (6-week course)
Number of subjects: 38
Study 8891847 — intervention group
Group type: COMPARATOR
Intervention: Both groups (interferon alone and combined therapy)
Number of subjects: 38
Study 8891847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha
Number of subjects: 38
Study 8891847 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 38
Study 1381022 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily (b.i.d.)
Number of subjects: 876
Study 1381022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg b.i.d.
Number of subjects: 876
Study 6383655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 227
Study 6383655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 30861455 — intervention group
Group type: EXPERIMENTAL
Intervention: DYNAMIC-ICU prediction rule
Number of subjects: 560
Study 31126299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks
Number of subjects: 62
Study 31126299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in rs9930506 risk allele carriers
Number of subjects: 62
Study 31126299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in AA genotype carriers
Number of subjects: 62
Study 31126299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in AG/GG genotype carriers
Number of subjects: 62
Study 28089180 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin (325 mg)
Number of subjects: 40
Study 28089180 — intervention group
Group type: EXPERIMENTAL
Intervention: PL2200 (modified-release lipid-based aspirin, 325 mg)
Number of subjects: 40
Study 28089180 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release enteric-coated (EC) aspirin (325 mg)
Number of subjects: 40
Study 25480541 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant prosthetic feet
Number of subjects: 11
Study 25480541 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant and Intermediate prosthetic feet
Number of subjects: 11
Study 25480541 — intervention group
Group type: COMPARATOR
Intervention: All prosthetic feet
Number of subjects: 11
Study 24307825 — intervention group
Group type: EXPERIMENTAL
Intervention: New Brush Group (changed toothbrush every month)
Number of subjects: 36
Study 24307825 — intervention group
Group type: COMPARATOR
Intervention: Old Brush Group (used single toothbrush for the whole period of the study)
Number of subjects: 36
Study 21199966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 3 weeks, 1-hour early-morning exposure to pale blue light at approximately 7500 lux
Number of subjects: 89
Study 21199966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT)
Number of subjects: 89
Study 21199966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dim red light, approximately 50 lux)
Number of subjects: 89
Study 19595483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablets (30mg for 3 days)
Number of subjects: 126
Study 19595483 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole capsules (30mg for 3 days)
Number of subjects: 126
Study 19595483 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 126
Study 19595483 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for orally disintegrating tablets
Number of subjects: 126
Study 16888641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiped clean method
Number of subjects: 25
Study 16888641 — intervention group
Group type: COMPARATOR
Intervention: Control lenses (not cleaned)
Number of subjects: 25
Study 14505239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoppa procedure
Number of subjects: 45
Study 14505239 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Lichtenstein procedure
Number of subjects: 45
Study 11890485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year support program based on nurse case management
Number of subjects: 100
Study 11890485 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100
Study 9513102 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft stabilizing appliance
Number of subjects: 23
Study 9513102 — intervention group
Group type: COMPARATOR
Intervention: Hard stabilizing appliance
Number of subjects: 23
Study 7995806 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video with differing realism conditions
Number of subjects: 0
Study 7995806 — intervention group
Group type: COMPARATOR
Intervention: Traditional values of objectivity and authenticity
Number of subjects: 0
Study 3142979 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 55
Study 3142979 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 55
Study 29763623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) in addition to temozolomide/radiotherapy
Number of subjects: 0
Study 29763623 — intervention group
Group type: COMPARATOR
Intervention: Control group (temozolomide/radiotherapy without BEV)
Number of subjects: 0
Study 26170014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron intervention
Number of subjects: 30
Study 26170014 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 23548532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 60
Study 23548532 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60
Study 23548532 — intervention group
Group type: COMPARATOR
Intervention: Control (no add-on)
Number of subjects: 60
Study 21667899 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 169
Study 21667899 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 169
Study 17999080 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mg/day doxycycline for 4‐6 weeks
Number of subjects: 67
Study 17999080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 855
Study 16837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 855
Study 16837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation
Number of subjects: 855
Study 12765924 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber (AC) with 200 micro g budesonide twice daily
Number of subjects: 30
Study 12765924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuchamber (NC) with 200 micro g budesonide twice daily
Number of subjects: 30
Study 12765924 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurement)
Number of subjects: 30
Study 10840911 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive packaging design
Number of subjects: 40
Study 10840911 — intervention group
Group type: COMPARATOR
Intervention: Non-deceptive packaging design
Number of subjects: 40
Study 9124243 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol maleate 0.5%
Number of subjects: 169
Study 9124243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carteolol hydrochloride 1%
Number of subjects: 169
Study 9124243 — intervention group
Group type: COMPARATOR
Intervention: Overall cardiovascular adverse effects
Number of subjects: 169
Study 8267038 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus low-dose aspirin (n = 12)
Number of subjects: 39
Study 8267038 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n = 22)
Number of subjects: 39
Study 7468550 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 45
Study 7468550 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine
Number of subjects: 45
Study 31397133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needle-knife with precise three-dimensional stereotactic localization of ashi points
Number of subjects: 74
Study 31397133 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided intrathecal injection (control group)
Number of subjects: 74
Study 27862108 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (CBT4BN)
Number of subjects: 191
Study 27862108 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face group cognitive-behavioral therapy (CBTF2F)
Number of subjects: 191
Study 27862108 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 191
Study 25932697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching and nurse case management (PC-NCM)
Number of subjects: 600
Study 25932697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching (PC)
Number of subjects: 600
Study 25932697 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 600
Study 23324964 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP (Ultraporous β-tricalcium phosphate)
Number of subjects: 55
Study 23324964 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP/BM (Ultraporous β-tricalcium phosphate combined with bone marrow aspirate)
Number of subjects: 55
Study 21262857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 2
Study 21262857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 19328598 — intervention group
Group type: EXPERIMENTAL
Intervention: Practidose individualised dispensing and dosing pillbox system
Number of subjects: 220
Study 19328598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 220
Study 16603337 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-implemented Reciprocal Imitation Training (RIT), implemented twice a week for 10 weeks.
Number of subjects: 3
Study 16603337 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-implemented RIT targeting object imitation.
Number of subjects: 3
Study 16603337 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-implemented RIT targeting both object and gesture imitation.
Number of subjects: 3
Study 16603337 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization assessed in families' homes at the end of treatment and a 1-month follow-up.
Number of subjects: 3
Study 16827430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hypertensive hemodilution (3H-therapy)
Number of subjects: 54
Study 16827430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 3H-therapy)
Number of subjects: 54
Study 12662378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine (20 mg twice daily)
Number of subjects: 122
Study 12662378 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg twice daily)
Number of subjects: 122
Study 10511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 patients (renal insufficiency)
Number of subjects: 53
Study 10511770 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype of ACE gene
Number of subjects: 53
Study 10511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of ACE-DD and AGT-TT genotypes
Number of subjects: 53
Study 10511770 — intervention group
Group type: COMPARATOR
Intervention: Group 1 patients (normal renal function)
Number of subjects: 53
Study 7556745 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol
Number of subjects: 33
Study 7556745 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 33
Study 7556745 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 33
Study 1706207 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 0
Study 1706207 — intervention group
Group type: COMPARATOR
Intervention: Deoxycoformycin
Number of subjects: 0
Study 1706207 — intervention group
Group type: COMPARATOR
Intervention: Chlorodeoxyadenosine
Number of subjects: 0
Study 1706207 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony stimulating factor
Number of subjects: 0
Study 1706207 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 0
Study 1706207 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agents or intensive chemotherapy
Number of subjects: 0
Study 6124236 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization
Number of subjects: 48
Study 6124236 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted version of the Masters and Johnson method
Number of subjects: 48
Study 6124236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (desensitization followed by Masters and Johnson)
Number of subjects: 48